[Unexpected Complications in the Withdrawal Treatment of the Research Chemical AH-7921].
We describe the case of a young male patient who had consumed the morphine-like substance AH-7921 which is available via the internet. He was initially admitted to hospital because of obstipation and presented within a day of inpatient treatment for the first time with a generalized tonic-clonic epileptic seizure with subsequent urinary retention. Within a few hours, the patient then also developed bradycardia, while at the same time describing symptoms of physical opioid withdrawal which gradually deteriorated within the following hours. We initiated a treatment with buprenorphine which resulted in a considerable reduction of withdrawal symptoms, so the patient could be discharged from hospital.
Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsmedizin Rostock.
A
A
Bernius
Institut für Rechtsmedizin, Universitätsmedizin Rostock.
V
V
Blaas
Institut für Rechtsmedizin, Universitätsmedizin Rostock.
D
D
Rentsch
Institut für Rechtsmedizin, Universitätsmedizin Rostock.
A
A
Büttner
Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsmedizin Rostock.
J
J
Thome
D000701:Analgesics, Opioid / Q000009:adverse effects*; D001549:Benzamides / Q000009:adverse effects*; D002047:Buprenorphine / Q000627:therapeutic use; D004830:Epilepsy, Tonic-Clonic / Q000209:etiology / Q000628:therapy; D006801:Humans; D008297:Male; D009292:Narcotic Antagonists / Q000627:therapeutic use; D013375:Substance Withdrawal Syndrome / Q000628:therapy*; D016055:Urinary Retention / Q000139:chemically induced / Q000628:therapy; D055815:Young Adult
D000701:Analgesics, Opioid; D001549:Benzamides; D009292:Narcotic Antagonists; D002047:Buprenorphine; C006215:AH 7921